Optimal management of taxane acute pain syndrome not clear

Managing peripheral neuropathy
Managing peripheral neuropathy
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome (TAPS) remains poorly researched.

Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 1-3 days and lasting 5-7 days after taxane-based chemotherapy. Despite negatively impacting patient’s quality of life, little is known about the optimal TAPS management. A systematic review of treatment strategies for TAPS across all tumor sites was performed.

READ FULL ARTICLE Curated publisher From Springer